201 related articles for article (PubMed ID: 9989840)
1. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer.
Yang XJ; Lecksell K; Gaudin P; Epstein JI
Am J Surg Pathol; 1999 Feb; 23(2):147-52. PubMed ID: 9989840
[TBL] [Abstract][Full Text] [Related]
2. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.
Oliai BR; Kahane H; Epstein JI
Am J Surg Pathol; 2002 Sep; 26(9):1151-60. PubMed ID: 12218571
[TBL] [Abstract][Full Text] [Related]
3. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer.
Varma M; Morgan M; Amin MB; Wozniak S; Jasani B
Histopathology; 2003 Feb; 42(2):167-72. PubMed ID: 12558749
[TBL] [Abstract][Full Text] [Related]
4. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
6. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
7. Negative 34betaE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases.
Halushka MK; Kahane H; Epstein JI
Hum Pathol; 2004 Jan; 35(1):43-6. PubMed ID: 14745723
[TBL] [Abstract][Full Text] [Related]
8. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract][Full Text] [Related]
9. Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity.
Curtis MW; Evans AJ; Srigley JR
Mod Pathol; 2005 Apr; 18(4):585-90. PubMed ID: 15778694
[TBL] [Abstract][Full Text] [Related]
10. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
11. Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Dalfior D; Delahunt B; Brunelli M; Parisi A; Ficarra V; Novara G; Novella G; Gobbo S; Valotto C; Chilosi M; Menestrina F; Martignoni G
Pathology; 2010 Jan; 42(1):1-5. PubMed ID: 20025473
[TBL] [Abstract][Full Text] [Related]
12. Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.
Turhan OI; Aydin NE; Sariyüce O; Ozkan S
Int Urol Nephrol; 1998; 30(6):731-44. PubMed ID: 10195869
[TBL] [Abstract][Full Text] [Related]
13. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
14. The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis.
Quick CM; Gokden N; Sangoi AR; Brooks JD; McKenney JK
Hum Pathol; 2010 Aug; 41(8):1145-9. PubMed ID: 20413145
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
16. The pattern of CD10 expression in selected pathologic entities of the prostate gland.
Tawfic S; Niehans GA; Manivel JC
Hum Pathol; 2003 May; 34(5):450-6. PubMed ID: 12792918
[TBL] [Abstract][Full Text] [Related]
17. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies.
Abrahams NA; Ormsby AH; Brainard J
Histopathology; 2002 Jul; 41(1):35-41. PubMed ID: 12121235
[TBL] [Abstract][Full Text] [Related]
18. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
19. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
20. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
